News

NeedleSmart PRO Receives FDA Approval

NeedleSmart PRO Receives FDA Approval
Covid-19
Member News

The award-winning NeedleSmart PRO needle destruction device has achieved FDA approval as a Class II medical device.

Merseyside Based NeedleSmart Ltd is the FIRST UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD).

The innovative NeedleSmart PRO device heats a sharp, contaminated hypodermic needle to 1,300, then compresses the molten metal into a smooth ball at the end of the syringe, removing the danger of needlestick injury and infection in just 6 seconds.

NeedleSmart’s patented technology is engineered in the UK, with offices in Knowsley, Merseyside (UK), and recently opened Pittsburgh, Pennsylvania (USA).

The NeedleSmart PRO will be used in clinical environments including hospitals and GP surgeries, and will be used in digital vaccination programmes and immunisations based in the North West.

The device offers many benefits

  • Reduction of needlestick injuries (NSI) and associated costs both emotional and financial.
  • Sustainability approx. 25% reduction in sharps bin requirement, leading to less waste, and contributing to the overall carbon footprint in the medical sector.
  • Potential introduction of clinisafe bag/box as no longer a sharp.
  • Along with associated software, the device will be used to digitalise vaccination data seamlessly, securely and safely.

Merseyside based NeedleSmart CEO Cliff Kirby added: “I am absolutely thrilled that the NeedleSmart PRO has received FDA approval. Knowing we are the first UK Company to achieve this is a fantastic achievement and pays testament to the product and expertise of our team, and we are looking forward new distribution partnerships in the USA.”

NeedleSmart is a smart med-tech business focused on better health results including safety, clinical process efficiency, cost management, and digitisation of clinical events, whilst improving sustainability. FDA approval marks a milestone in NeedleSmart’s geographic expansion to serve the North American market.

For more information & images please contact:

julie@needlesmart.com

+44 (0)7850630004

T: +44 (0)151 315 0500 (UK)

T: +1 (717) 8561296 (USA)

needlesmart.com

digitalvaccination.com

NEWS​

Related News

Evondos Anna in Siun Sote, Finland: Technology brings quality home care to sparsely-populated areas

9 Apr 2024
In Siun Sote, it is believed that medicine-dispensing robots will increasingly establish themselves as part of future home care. In North Karelia, dem...

ECHAlliance Announces Reciprocal Agreement with AgeTech Atlanta

8 Apr 2024
ECHAlliance and AgeTech Atlanta forge a Foundation Partnership to drive AgeTech Innovation and Excellence

Digital Health Collaboration: ECHAlliance Session at Africa-Europe Science Forum

8 Apr 2024
Connecting the Dots: ECHAlliance Hosts session on Digital Health Collaboration at Africa-Europe Science Collaboration and Innovation Forum

New Foundations 2024

8 Apr 2024
New Foundations is a key driver in progressing our strategic priorities by enabling awardees to pursue research, networking or dissemination activitie...

Neurotech Entrepreneurship to Validate Emerging Innovations (NERVE)

8 Apr 2024
The NERVE (Neurotech Entrepreneurship to Validate Emerging Innovations) program is Canada's single largest award that catalyzes early stage entreprene...

Horizon Europe Pump Priming Programme

8 Apr 2024
The programme supports individual UK SMEs wanting to explore and access Horizon Europe collaborative research and innovation opportunities.

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *